By ANDREW POLLACK
Solanezumab, from Eli Lilly, is getting another look for mild cases, and Biogen said data from a small group taking aducanumab showed mixed results.
Published: July 23, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1g4nMHK
Subscribe
Login
0 Comments
Newest
- Related Content by Tag
- NYT